Terminated PHASE3 INTERVENTIONAL 2-arm NCT00679627

A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease

A Randomized, Double-Blind, Placebo-controlled Trial of Long-term (2-year) Treatment of Galantamine in Mild to Moderately-Severe Alzheimer's Disease

Sponsor: Janssen Research & Development, LLC

Conditions Alzheimer's Disease

Interventions Galantamine Placebo

Updated 12 times since 2017 Last updated: Sep 10, 2013 Started: Jun 30, 2008 Primary completion: Apr 30, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to a pre-specified imbalance of deaths between treatment groups, the DSMB recommended early termination of the trial

Other terminated trials from Janssen Research & Development, LLC

More terminations from Janssen Research & Development, LLC

Other Alzheimer's Disease trials with similar outcome

Browse all Alzheimer's Disease trials

A PHASE3 clinical study on Alzheimer's Disease, this trial is terminated or withdrawn. The trial is conducted by Janssen Research & Development, LLC and has accumulated 12 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

12 versions recorded

Oct 2025 — Present [monthly]

Terminated PHASE3
Sep 2025 — Oct 2025 [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3

▶ Show 7 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Nov 2020 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Aug 2017 — May 2018 [monthly]

Terminated PHASE3
Feb 2017 — Aug 2017 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Research & Development, LLC

Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arad, Romania , Athens, Greece , Bad Aibling, Germany , Bad Homburg, Germany , Bad Honnef, Germany , Bamberg, Germany , Berlin, Germany , Bielefeld, Germany , Bochum, Germany , Bratislava, Slovakia and 85 more locations